310 related articles for article (PubMed ID: 21673033)
1. Protection of MP-12-vaccinated rhesus macaques against parenteral and aerosol challenge with virulent rift valley fever virus.
Morrill JC; Peters CJ
J Infect Dis; 2011 Jul; 204(2):229-36. PubMed ID: 21673033
[TBL] [Abstract][Full Text] [Related]
2. Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids.
Morrill JC; Mebus CA; Peters CJ
Am J Vet Res; 1997 Oct; 58(10):1110-4. PubMed ID: 9328663
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle.
Morrill JC; Mebus CA; Peters CJ
Am J Vet Res; 1997 Oct; 58(10):1104-9. PubMed ID: 9328662
[TBL] [Abstract][Full Text] [Related]
4. Mucosal immunization of rhesus macaques with Rift Valley Fever MP-12 vaccine.
Morrill JC; Peters CJ
J Infect Dis; 2011 Aug; 204(4):617-25. PubMed ID: 21791664
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves.
von Teichman B; Engelbrecht A; Zulu G; Dungu B; Pardini A; Bouloy M
Vaccine; 2011 Aug; 29(34):5771-7. PubMed ID: 21664400
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep.
Dungu B; Louw I; Lubisi A; Hunter P; von Teichman BF; Bouloy M
Vaccine; 2010 Jun; 28(29):4581-7. PubMed ID: 20470792
[TBL] [Abstract][Full Text] [Related]
7. Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep.
Morrill JC; Carpenter L; Taylor D; Ramsburg HH; Quance J; Peters CJ
Vaccine; 1991 Jan; 9(1):35-41. PubMed ID: 2008798
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of three candidate Rift Valley fever vaccines in sheep.
Kortekaas J; Antonis AF; Kant J; Vloet RP; Vogel A; Oreshkova N; de Boer SM; Bosch BJ; Moormann RJ
Vaccine; 2012 May; 30(23):3423-9. PubMed ID: 22449427
[TBL] [Abstract][Full Text] [Related]
9. Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.
Ikegami T
Expert Rev Vaccines; 2017 Jun; 16(6):601-611. PubMed ID: 28425834
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of Rift Valley fever MP-12 and arMP-12ΔNSm21/384 vaccine candidates in goats (Capra aegagrus hircus) from Tanzania.
Nyundo S; Adamson E; Rowland J; Palermo PM; Matiko M; Bettinger GE; Wambura P; Morrill JC; Watts DM
Onderstepoort J Vet Res; 2019 Jan; 86(1):e1-e8. PubMed ID: 30843406
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a recombinant Rift Valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep.
Weingartl HM; Nfon CK; Zhang S; Marszal P; Wilson WC; Morrill JC; Bettinger GE; Peters CJ
Vaccine; 2014 Apr; 32(20):2345-9. PubMed ID: 24462482
[TBL] [Abstract][Full Text] [Related]
12. Four-segmented Rift Valley fever virus induces sterile immunity in sheep after a single vaccination.
Wichgers Schreur PJ; Kant J; van Keulen L; Moormann RJ; Kortekaas J
Vaccine; 2015 Mar; 33(12):1459-64. PubMed ID: 25665959
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Efficacy, Potential for Vector Transmission, and Duration of Immunity of MP-12, an Attenuated Rift Valley Fever Virus Vaccine Candidate, in Sheep.
Miller MM; Bennett KE; Drolet BS; Lindsay R; Mecham JO; Reeves WK; Weingartl HM; Wilson WC
Clin Vaccine Immunol; 2015 Aug; 22(8):930-7. PubMed ID: 26041042
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves.
Morrill JC; Laughlin RC; Lokugamage N; Wu J; Pugh R; Kanani P; Adams LG; Makino S; Peters CJ
Vaccine; 2013 Oct; 31(43):4988-94. PubMed ID: 23994375
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a formalin-inactivated Rift Valley fever vaccine in sheep.
Harrington DG; Lupton HW; Crabbs CL; Peters CJ; Reynolds JA; Slone TW
Am J Vet Res; 1980 Oct; 41(10):1559-64. PubMed ID: 7224281
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans.
Pittman PR; McClain D; Quinn X; Coonan KM; Mangiafico J; Makuch RS; Morrill J; Peters CJ
Vaccine; 2016 Jan; 34(4):424-429. PubMed ID: 26718688
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of two next-generation Rift Valley fever vaccines.
Kortekaas J; Oreshkova N; van Keulen L; Kant J; Bosch BJ; Bouloy M; Moulin V; Goovaerts D; Moormann RJ
Vaccine; 2014 Sep; 32(39):4901-8. PubMed ID: 25050973
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep.
Morrill JC; Laughlin RC; Lokugamage N; Pugh R; Sbrana E; Weise WJ; Adams LG; Makino S; Peters CJ
Vaccine; 2013 Jan; 31(3):559-65. PubMed ID: 23153443
[TBL] [Abstract][Full Text] [Related]
19. Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever.
Wallace DB; Ellis CE; Espach A; Smith SJ; Greyling RR; Viljoen GJ
Vaccine; 2006 Nov; 24(49-50):7181-9. PubMed ID: 16870311
[TBL] [Abstract][Full Text] [Related]
20. Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus.
Kortekaas J; Dekker A; de Boer SM; Weerdmeester K; Vloet RP; de Wit AA; Peeters BP; Moormann RJ
Vaccine; 2010 Mar; 28(11):2271-6. PubMed ID: 20079874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
